Epigenetic Mechanisms in Cancer, Vol 3. Translational Epigenetics

  • ID: 4226448
  • Book
  • 392 Pages
  • Elsevier Science and Technology
1 of 4
Epigenetic Mechanisms in Cancer provides a comprehensive analysis of epigenetic signatures that govern disease development, progression and metastasis. Epigenetic signatures dictating tumor etiologies present an opportunity for biomarker identification which has broad potential for improving diagnosis, prognosis, prediction, and risk assessment.  This volumes offers a unique evaluation of signature differences in childhood, sex-specific and race-specific cancers, and in doing so broadly illuminates the scope of epigenetic biomarkers in clinical environments. Chapters detail the major epigenetic process in humans consisting of DNA methylation, histone modifications and microRNAs (miRNAs) involved in the initiation, progression and metastasis of tumors. Also delineated are recent technologies such as next generation sequencing that are used to identify epigenetic profiles (primarily methylation analysis) in samples (normal, benign and cancerous) and which are highly important to the analysis of epigenetic outcomes.

- Offers broad coverage that is applicable to audiences in various area of cancer research - population studies, diagnostics, prognosis, prediction, therapy, risk, etc.- Provides critical review analysis of the topics that will clarify and delineate the potential roles of epigenetic signatures in cancer management- Covers basic, as well as, clinical areas of epigenetic mechanisms in tumorigenesis- Features contributions by leading experts in the field- Provides comprehensive coverage of current epigenetic signatures involved in the etiology of various cancers and miRNAs

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Note: Product cover images may vary from those shown
2 of 4

1. Epigenetic Regulation in Pediatric Leukemia 2. Role of Epigenetics in testicular cancer 3. Changes in the epigenetic landscape of prostate cancer 4. Epigenetic health disparities and colon cancer 5. Genetic and epigenetic modifications in pancreatic cancer 6. Epigenetics of Breast Cancer 7. Epigenetic Modulations in Ovarian Cancer 8. Epigenetic Epidemiology for Cancer Risk 9. Epigenetic biomarkers in cancer epidemiology 10. Epigenetic biomarkers and racial differences in cancer 11. Epigenetic predictive biomarkers 12. Epigenetic signatures in the diagnosis and prognosis of cancer 13. Future Challenges and Prospects for the role of epigenetic mechanism in cancer management

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Saldanha, Sabita
Dr. Saldanha is an Assistant Professor in the Department of Biological Sciences at Alabama State University. Her current research project includes the therapeutic role of histone deacetylase inhibitors in colon and prostate cancers, and her areas of epigenetic interest include epigenetic markers as effective tools in cancer diagnosis. She has more than fifteen years of research experience in cancer epigenetics, protein biochemistry, molecular biology and cloning. She has twelve years of teaching experience and has been a STEM faculty mentor, MARC mentor, and Honor's program project director at ASU. Recently, Dr. Saldanha was named the 2015 National Academies Education Fellow in Life Sciences. She is also currently a Health Disparities Research and Training Program Scholar at UAB and a member of the Cancer Biology Research and Training program at ASU, which was established in 2015. She serves as senior personnel for the ASU-UAB Comprehensive Cancer Center partnership and has been instrumental in developing a cancer biology course at ASU.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll